Synthesis and physicochemical characterization of novel phenotypic probes targeting the nuclear factor-kappa B signaling pathway

  1. Paul M. Hershberger1,
  2. Satyamaheshwar Peddibhotla1,
  3. E. Hampton Sessions1,
  4. Daniela B. Divlianska1,
  5. Ricardo G. Correa2,
  6. Anthony B. Pinkerton2,
  7. John C. Reed2 and
  8. Gregory P. Roth1

1Conrad Prebys Center for Chemical Genomics, Sanford-Burnham Medical Research Institute at Lake Nona, 6400 Sanger Road Orlando, FL 32827, USA
2Sanford-Burnham Medical Research Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA

  1. Corresponding author email

This article is part of the Thematic Series "Synthetic probes for the study of biological function".

Guest Editor: J. Aubé
Beilstein J. Org. Chem. 2013, 9, 900–907. doi:10.3762/bjoc.9.103
Received 16 Jan 2013, Accepted 22 Apr 2013, Published 08 May 2013

Abstract

Activation of nuclear factor-kappa B (NF-κB) and related upstream signal transduction pathways have long been associated with the pathogenesis of a variety of inflammatory diseases and has recently been implicated in the onset of cancer. This report provides a synthetic and compound-based property summary of five pathway-related small-molecule chemical probes identified and optimized within the National Institutes of Health-Molecular Libraries Probe Center Network (NIH-MLPCN) initiative. The chemical probes discussed herein represent first-in-class, non-kinase-based modulators of the NF-κB signaling pathway, which were identified and optimized through either cellular phenotypic or specific protein-target-based screening strategies. Accordingly, the resulting new chemical probes may allow for better fundamental understanding of this highly complex biochemical signaling network and could advance future therapeutic translation toward the clinical setting.

Keywords: ML029; ML130; ML146; ML236; ML237

Introduction

The Molecular Libraries Network was established in 2005 as an academic pilot-scale (MLSCN) screening effort for exploring potential new therapeutic targets stemming from the human genome project. After initial successes in high-throughput chemical screening (HTS), efforts in medicinal chemistry and exploratory pharmacology were added in order to leverage and advance the small-molecule compounds discovered within the HTS process. The program then advanced a broader probe-production initiative (MLPCN) in 2008. This consortium resulted in the harnessing of chemical biology resources from four comprehensive centers and five specialty centers, which focused on either medicinal chemistry or a specific technical screening capability as an overall academic, collaborative scientific network [1]. In general terms, the overall vision and NIH mission encompasses the discovery of unique chemical tools that will be useful to interested scientific investigators to assist them with advancing basic in vitro and in vivo studies for testing new hypotheses in disease modulation.

Within this report, the outcomes of two Sanford-Burnham projects for chemical probe discovery are discussed, highlighting five examples of thematic small-molecule chemical probes discovered through our center’s efforts. Within the realm of immunology and inflammation research, many cellular pathways leading to the activation of NF-κB family of transcription factors have been identified and several excellent reviews are available [2-5]. In general, these pathways have been shown to participate in host defense, immunity, and inflammation and even have implications in cancer. Thus, dysregulation of NF-κB activity contributes to numerous autoimmune and inflammatory disease states. With this, the availability of new chemical pathway probes will further enhance understanding of this complex network.

The first project encompassed the synthesis and characterization of three phenotypic probes designed to be selective modulators of the NF-κB signaling pathway in either human embryonic kidney (HEK) 293, HEK 293T or pre-B leukemia 697 cells. The second project focused on two probes that are target-oriented within the NF-κB pathway and are specific modulators of the intracellular signaling protein, nucleotide-binding oligomerization domain-1 (NOD1).

Within each project area first-in-class chemical probes were identified and characterized as new research-tool compounds. The synthetic routes for each probe, including their general physicochemical and pharmacological properties, are summarized in this report.

Results and Discussion

Phenotypic screening for noncanonical NF-κB pathway selective inhibitors of IL-8 production in HEK 293, HEK 293T (ML029) and 697 pre-B cells (ML236 and ML237): Most pathways for NF-κB activation converge on the IκB kinases (IKKs), and more than nine signaling routes have been identified [6]. While IKKs therefore represent attractive targets for drug discovery programs, the selectivity envisioned for an acceptable therapeutic index has remained elusive as inhibitors of IKKs indiscriminately suppress all known NF-κB activation pathways. Within this project, new probes were sought that were not active via the currently known receptor-driven pathways and IκB kinases, but attenuated NF-κB transcriptional activity as measured by a luciferase-based reporter gene assay with validation using a panel of known receptor and kinase-based counter screens [7].

Because activation of NF-κB is known to be initiated through protein kinase C (PKC), we hypothesized that selectivity could be possible by the fact that PKC activation occurs downstream from cell membrane antigen and growth-factor receptors yet is still upstream of IKKγ, potentially by inhibition of a new target protein or novel protein–protein interaction. Using cell-based HTS reporter gene assays, a series of chemical probes were identified that selectively inhibit this unique PKC-induced NF-κB pathway without modulating other NF-κB activation pathways such as those including the cytosolic proteins CARMA1, Bcl-10, MALT1, TRAF6 and Ubc13 [8].

The first probe identified within this series was the benzimidazole ML029 (4), which exhibited an IC50 of 0.07 μM in the HEK 293 cell assay with corresponding well-defined structure–activity relationships (SAR) through analogue synthesis [9]. This probe was discovered after two separate screening campaigns totaling ~110,000 compounds. At concentrations up to 8 μM, 4 failed to suppress PKCβ and PKCθ (the PKC family members implicated in TCR/BCR signaling) and IKKβ, while known PKC and IKK inhibitors and the broad-spectrum kinase inhibitor staurosporine afforded potent inhibition [9-11]. Further selectivity profiling revealed that 4 inhibited (>50% at 10 uM) only 3 out of the 353 kinases surveyed by using a KINOMEscan™ (DiscoveRx) platform. None of these 3 (TLK1 (70% inhibition), Raf (57%), and JAK2 (53%)) are relevant to NF-κB pathway regulation.

To prepare 4, a synthetic route (Scheme 1) was optimized in a manner that allowed for the preparation of related analogues [9]. The intermediate 1 was prepared through condensation of 4,5-dimethylbenzene-1,2-diamine with potassium ethyl xanthate in ethanol under reflux. Bromination of 1 led to the key intermediate 2-bromo-5,6-dimethylbenzimidazole (2), which reacted smoothly with 3-aminopropanol to give the amine 3 in high yield and purity after extraction. The solvent-free microwave process employed was superior to traditional oil-bath thermal heating, which tended to generate crude material requiring extensive purification. Ultimately, probe 4 was prepared (Scheme 1, Method A) in moderate yield by reaction of 3 with α-bromo-3,5-di-tert-butyl-4-hydroxyacetophenone in n-butanol under reflux. Importantly, formation of the tricyclic condensation side product 5 was completely eliminated by performing the reaction with sodium bicarbonate at 23 °C in methanol (Scheme 1, Method B). Thus, compound 4 was isolated as a lyophilized white powder in 78% yield and >98% purity.

[1860-5397-9-103-i1]

Scheme 1: Synthesis of ML029 (4).

Deeper in vitro biological investigation using 4 as a chemical probe showed that it was not active (>30 μM) in more physiologically relevant HEK 293T and 697 pre-B cell lines. Therefore, an HTS campaign was initiated to identify compounds active in these specific cell subtypes by using the established HTS NF-κB reporter gene assay format. This included screening of a larger (~330,600 compound) MLSMR collection to ensure identification of additional chemical scaffolds not previously available. From this campaign two new cell-active NF-κB inhibitors were derived that were both selective against the NF-κB pathway induced by known PKC activators (phorbol myristic acetate (PMA)/ionomycin) and were selective toward the 697 pre-B cell line. It is interesting to note that no compounds meeting probe selectivity criteria were identified within the T cell (HEK 293T) specific assay. The first oxadiazole-based probe ML236 (8) was potent (0.035 μM) in the 697 pre-B cell line and >400-fold selective over both the NF-κB activation in HEK 293T cells and against TNFα-mediated NF-κB activation. In comparison, the second oxazole-based probe 12 is also potent (0.2 μM) in the 697 pre-B cell line and >400-fold selective over both the NF-κB activation in HEK 293T cells and against TNFα mediated NF-κB activation as measured in our reporter gene assay format.

Probe 8 was synthesized as shown in Scheme 2 [12]. Reaction of 4-tert-butyl-cyanobenzene with hydroxylamine hydrochloride under microwave heating conditions resulted in the hydroxyamidine 6. This intermediate was condensed with succinic anhydride to provide the oxadiazole acid 7. Conversion of 7 to the corresponding acid chloride and subsequent amidation with excess methylamine afforded 8 in excellent yield after normal phase chromatography. This route was employed to make a variety of analogues and was generally conducted efficiently without purification of any intermediates. This enabled several analogues to be prepared in parallel, using mass-directed reverse-phase preparative HPLC to recover the pure isolates.

[1860-5397-9-103-i2]

Scheme 2: Synthesis of ML236 (8).

The second related probe, ML237, (12) was synthesized as shown in Scheme 3 [12]. Commercially available 4-ethoxybenzaldehyde was condensed with diacetyl monoxime under acidic conditions. The resulting oxazole N-oxide 9 was converted to the chloromethyloxazole 10 via selective chlorination with phosphorous oxychloride in good yield. Addition of thioglycolic acid led to the carboxylic acid 11, which was coupled to cyclopropylamine to give 12 using a standard amidation protocol. The compound was purified by normal phase chromatography and was recovered as a white solid with a sharply defined melting point. The route was also amenable toward the preparation of related analogues. Generally, 9 was used without purification and the entire route was conducted efficiently without chromatographic purification of intermediates.

[1860-5397-9-103-i3]

Scheme 3: Synthesis of ML237 (12).

As a summary of project one, three novel chemical probes were discovered and optimized within this initiative. Tractable and efficient synthetic routes have been developed and are reported. One HEK 293T and two 697 pre-B cell specific probes are now available as research tools either through the Sanford-Burnham Center or through commercial sources. These probes were identified from a phenotypic screen and thus the precise cellular protein target is yet to be identified. Each probe performs in a noncanonical manner and inhibits NF-κB activity outside of the known, well-characterized pathways [7]. Determination of the precise signaling mechanism is the subject of ongoing research in our laboratories.

Discovering modulators of NF-κB signaling via selective nucleotide-binding oligomerization domain-1 (NOD1) inhibition (ML130 and ML146): The second program targeted proteins in the mammalian innate immune system that confer defense by detection of specific microbial ligands, or pathogen-associated molecular pattern microbial sensors known to house NOD1 (nucleotide-binding oligomerization domain-1 protein). Dysregulation of the NOD signaling pathway is also strongly associated with exacerbation of postinfection systemic disease states; however, its upregulation at the gene level can enhance systemic innate immunity [13]. The NOD1 cytosolic bacterial sensor falls within this class of NF-κB transcription pathway activators [14]. The NOD-like receptor (NLR) family reportedly comprises a large number of proteins from both vertebrate and invertebrate animal species, with >20 human proteins recognized [15-21]. Some NLR proteins have been shown to detect bacterial cell-wall components including lipopolysaccharides and/or peptidoglycan (NOD1 or 2) along with those of bacterial flagellin [22-25]. Importantly, the NOD1 protein primarily recognizes Gram-negative bacteria, in contrast to the more widely studied sensor NOD2, which participates in immunity against Gram-positive bacteria. Additionally, NOD1 has been associated with the induction of NF-κB activation, caspase-1 activation and apoptosis [26-28]. Genetic mutations in NOD are associated with numerous inflammatory conditions, including Crohn’s disease and pancreatitis [29-34]. The identification of probes relevant to the NOD family of NLR proteins will improve understanding of the NOD1-mediated signaling pathway and also may translate to the discovery of new therapeutics for inflammatory diseases.

Probes ML130 (13) and ML146 (17) were identified as NOD1-selective molecules from an HTS campaign involving ~290,000 compounds. Compound 13 (IC50 = 0.52 μM) and compound 17 (IC50 = 1.54 μM) each inhibited γ-tri-DAP-stimulated (a gamma-tri-diaminopimelic acid derivative and NOD1-dependent signaling ligand) luciferase production in HEK 293T cells, which has endogenous NOD1 levels at submicromolar concentration as determined in a NF-κB-linked reporter assay. Both probes selectively (>40-fold for 13, >8-fold for 17) inhibited NOD1-dependent activation of the NF-κB pathway without inhibiting MDP-stimulated (muramyl dipeptide and a NOD2-dependent signaling ligand) signal transduction in reporter cell lines containing either low or overexpressed NOD2 proteins. Probes 13 and 17 were also selective over the non-NOD-stimulated NF-κB pathways (TNF-α, doxorubicin and PMA/ionomycin) in these reporter assays. Both of the probes, and their close analogues as discovered through SAR studies, selectively inhibited IL-8 secretion and the biologically relevant terminal effect of NOD1 (γ-tri-DAP) dependent NF-κB activation. Additionally, they neither inhibited NOD2-dependent nor TNF-α-dependent IL-8 secretion in biologically relevant MCF-7 cells. While 13 is the more potent and selective of these probes, 17 also met probe criteria and represents a second bonafide scaffold for a NOD1-selective probe.

ML130 (13) was synthesized as shown in Scheme 4 [35]. Commercially available 2-aminobenzimidazole was treated with p-toluenesulfonyl chloride in the presence of pyridine to obtain 13. By performing the reaction at high concentration, it was generally simple to purify the reaction mixture directly without work up using normal-phase chromatography.

[1860-5397-9-103-i4]

Scheme 4: Synthesis of ML130 (13).

ML146 (17) was synthesized as shown in Scheme 5. Commercially available 6-amino-1-methyluracil was brominated to give 14, which was reacted without purification with crotylamine under microwave heating conditions to provide 15. Reaction of 15 with potassium ethyl xanthogenate, again under microwave heating conditions, led to the bicyclic thiol 16. Without purification, 16 was added to 1-bromo-3-phenylpropane in the presence of potassium carbonate to provide 17. Several analogues were efficiently prepared without chromatographic purification of intermediates, and the final compounds were purified by normal-phase chromatography if necessary [12].

[1860-5397-9-103-i5]

Scheme 5: Synthesis of ML146 (17).

As a summary of the second project, two novel chemical probes that are selective for NOD1 but not NOD2 signaling, were discovered and optimized within the scope of the program. Tractable and efficient synthetic methods have been employed and are reported. Both NOD1 selective probes are now available as research tools either through the Sanford-Burnham Center or through commercial sources.

Chemical probe physicochemical and pharmacological properties

Overall, the project probes presented physicochemical properties consistent with those of well-recognized drug-like molecules (Table 1). Molecular weights ranged from 287 to 465 g/mol. Calculated log P values were between 3.1 and 3.5 with the exception of 4, which had an exceptionally high lipophilic value of 7.2 due to the presence of two tert-butyl moieties on the phenyl ring. The probes all contain from one to five H-bond donors and acceptors, and polar surface areas ranging from 67 to 90 Å2. Based on current hit-to-lead trends within the pharmaceutical industry, all probes discussed provide qualified starting points for advanced lead-optimization programs.

Table 1: Calculated properties of probes.

Property 4 8 12 13 17
Molecular weight [g/mol] 465.6 287.3 346.4 287.3 370.4
Molecular formula C28H39N3O3 C16H21N3O2 C18H22N2O3S C14H13N3O2S C19H22N4O2S
XLogP3-AA 7.2 3.0 3.1 3.2 3.5
H-Bond donors 3 1 1 1 1
H-Bond acceptors 5 4 4 4 3
Polar surface area [Å2] 85.2 68.0 89.7 86.4 67.2
Heavy atom count 34 21 24 20 26

The probes were evaluated using known in vitro ADME/T assays to understand their overall pharmacological properties (Table 2). Probe 4 exhibited good solubility especially as the pH decreased from 6.2 to 5, thereby mitigating the high calculated log P to some degree. Probes 8 and 12 also showed good solubility. Probe 13 had moderate solubility, and 17 showed the lowest solubility across the pH range but still approximately equal to its IC50 value. The PAMPA (parallel artificial membrane permeability assay) assay is used as an in vitro model of passive, transcellular permeability. An artificial membrane immobilized on a filter is placed between a donor and acceptor compartment. In this test, the probes exhibited good cell permeability overall. Although metabolic stability was poor in the presence of murine microsomes, all five probes were more stable in the presence of human hepatic microsomes. Most notably, 8 showed no apparent instability when subjected to human hepatic microsomes after one hour of exposure. It is not yet known whether it represents a species specific CPY450 inhibitor. Importantly, none of the probes showed evidence of cytotoxicity in immortalized human hepatocyctes (Fa2N-4 cells) and in the NCI-60 cell line cytotoxicity panel with 10 and 50 μM test concentrations [36].

Table 2: Summary of in vitro ADME/T properties of probes.

Property 4 8 12 13 17
Aqueous solubility
(μM)
pH 5.0/6.2/7.4
90/1.1/1.5 92/101/103 112/133/160 7.0/5.9/7.0 1.5/1.8/1.7
PAMPA Pe (10−6 cm/s)a
Donor pH: 5.0/6.2/7.4
Acceptor pH: 7.4
299/710/441 751/755/746 513/541/59 491/562/382 1269/1516/1344
Hepatic microsome stabilityb
Human/mouse
(% remaining)
26/0.5 100/4.9 22.7/0 41.8/0.8 8.8/0.86
Hepatic toxicity
LC50 (µM)
>50 >50 >50 >50 >50

aCompound at 50 μM (typical PAMPA Pe permeability classification: low 5 × 10−6, moderate 250 × 10−6, high 1000 × 10−6); bCompound at 1 μM, 60 min.

Conclusion

The high-throughput screening of cell-based phenotypic and specific NOD1 protein-based assay targets within the NF-κB pathway has generated a series of unique chemical probes that are now available and useful for investigators to access and utilize in future studies. The compounds are well characterized using in vitro assay panels and are not pathway-associated kinase-family inhibitors. Research efforts are ongoing to improve molecular potency and properties to make each chemical scaffold family suitable for advanced in vivo studies. Each probe represents a low-molecular-weight, “rule of 5” compliant starting point for target identification or lead optimization efforts. In screening the MLSMR, and with subsequent analogue synthesis, we have demonstrated that unique and tractable hits can be identified by using the available NIH-MLSMR compound collection.

Supporting Information

Supporting Information File 1: Experimental procedures for synthesizing compounds 14 and 617.
Format: PDF Size: 165.0 KB Download
Supporting Information File 2: NMR Spectra for ML029 (4), ML236 (8), ML237 (12), ML130 (13) and ML146 (17).
Format: PDF Size: 436.9 KB Download

Acknowledgements

The authors thank Michael Vicchiarelli and Arianna Mangravita-Novo in the SBMRI pharmacology Core for providing the ADME/T pharmacological profile data, and Paul Diaz for contributions to the NF-κB research program in the John Reed lab. We also gratefully recognize SBMRI compound management, assay development, HTS and Medicinal Chemistry Core team efforts in enabling these projects that resulted in the reported chemical probes and related analogues. We thank Dr.’s Pasha Khan and Jun Pu for synthetic efforts within these projects. This work was supported under federal grants U54 HG005033, R03 MH084844 and U01 AI078048 to JCR.

References

  1. Molecular Libraries Program. http://mli.nih.gov/mli/mlpcn/.
    Return to citation in text: [1]
  2. Tracey, K. J.; Cerami, A. Annu. Rev. Cell Biol. 1993, 9, 317–343. doi:10.1146/annurev.cb.09.110193.001533
    Return to citation in text: [1]
  3. Baud, V.; Karin, M. Nat. Rev. Drug Discovery 2009, 8, 33–40. doi:10.1038/nrd2781
    Return to citation in text: [1]
  4. Bonizzi, G.; Karin, M. Trends Immunol. 2004, 25, 280–288. doi:10.1016/j.it.2004.03.008
    Return to citation in text: [1]
  5. Gilmore, T. D. Oncogene 2006, 25, 6680–6684. doi:10.1038/sj.onc.1209954
    Return to citation in text: [1]
  6. Karin, M.; Delhase, M. Semin. Immunol. 2000, 12, 85–98. doi:10.1006/smim.2000.0210
    Return to citation in text: [1]
  7. Shi, R.; Re, D.; Dudl, E.; Cuddy, M.; Okolotowicz, K. J.; Dahl, R.; Su, Y.; Hurder, A.; Kitada, S.; Peddibhotla, S.; Roth, G. P.; Smith, L. H.; Kipps, T. J.; Cosford, N.; Cashman, J.; Reed, J. C. ACS Chem. Biol. 2010, 5, 287–299. doi:10.1021/cb9003089
    Return to citation in text: [1] [2]
  8. Thome, M. Nat. Rev. Immunol. 2004, 4, 348–359. doi:10.1038/nri1352
    Return to citation in text: [1]
  9. Peddibhotla, S.; Shi, R.; Khan, P.; Smith, L. H.; Mangravita-Novo, A.; Vicchiarelli, M. I.; Su, Y.; Okolotowicz, K. J.; Cashman, J. R.; Reed, J. C.; Roth, G. P. J. Med. Chem. 2010, 53, 4793–4797. doi:10.1021/jm1000248
    Return to citation in text: [1] [2] [3]
  10. For assay details see Supporting Information File 1 and PubChem link to AIDs 465 and 1384; http://pubchem.ncbi.nlm.nih.gov/assay/assay.cgi?aid=465; http://pubchem.ncbi.nlm.nih.gov/assay/assay.cgi?aid= 1384).
    Return to citation in text: [1]
  11. Okolotowicz, K. J.; Shi, R.; Zheng, X.; MacDonald, M.; Reed, J. C.; Cashman, J. R. Bioorg. Med. Chem. 2010, 18, 1918–1924. doi:10.1016/j.bmc.2010.01.039
    Return to citation in text: [1]
  12. All published MLPCN probe reports can be found within the public resource known as the NCBI Bookshelf: http://mli.nih.gov/mli/mlp-probes/ This page has a link called “Probe Report Web Table”, which accesses an Excel file that allows released probe reports to be viewed. Reports for ML029, ML130, and ML146 are viewable as of 11 Jan 2013; the report for ML236 and ML237 should be released to this site in 2013.
    Return to citation in text: [1] [2] [3]
  13. Clarke, T. B.; Davis, K. M.; Lysenko, E. S.; Zhou, A. Y.; Yimin, Y.; Weiser, J. N. Nat. Med. 2010, 16, 228–231. doi:10.1038/nm.2087
    Return to citation in text: [1]
  14. Strober, W.; Murray, P. J.; Kitani, A.; Watanabe, T. Nat. Rev. Immunol. 2006, 6, 9–20. doi:10.1038/nri1747
    Return to citation in text: [1]
  15. Chamaillard, M.; Girardin, S. E.; Viala, J.; Philpott, D. J. Cell. Microbiol. 2003, 5, 581–592. doi:10.1046/j.1462-5822.2003.00304.x
    Return to citation in text: [1]
  16. Inohara, N.; Nuñez, G. Nat. Rev. Immunol. 2003, 3, 371–382. doi:10.1038/nri1086
    Return to citation in text: [1]
  17. Inohara, N.; Nuñez, G. Oncogene 2001, 20, 6473–6481. doi:10.1038/sj.onc.1204787
    Return to citation in text: [1]
  18. Inohara, N.; Ogura, Y.; Nuñez, G. Curr. Opin. Immunol. 2002, 5, 76–80.
    Return to citation in text: [1]
  19. Kawai, T.; Akira, S. Int. Immunol. 2009, 21, 317–337. doi:10.1093/intimm/dxp017
    Return to citation in text: [1]
  20. Rietdijk, S. T.; Burwell, T.; Bertin, J.; Coyle, A. J. Curr. Opin. Pharmacol. 2008, 8, 261–266. doi:10.1016/j.coph.2008.04.003
    Return to citation in text: [1]
  21. Murray, P. J. Curr. Opin. Immunol. 2005, 17, 352–358. doi:10.1016/j.coi.2005.05.006
    Return to citation in text: [1]
  22. Girardin, S. E.; Boneca, I. G.; Viala, J.; Chamaillard, M.; Labigne, A.; Thomas, G.; Philpott, D. J.; Sansonetti, P. J. J. Biol. Chem. 2003, 278, 8869–8872. doi:10.1074/jbc.C200651200
    Return to citation in text: [1]
  23. Chamaillard, M.; Hashimoto, M.; Horie, Y.; Masumoto, J.; Qiu, S.; Saab, L.; Ogura, Y.; Kawasaki, A.; Fukase, K.; Kusumoto, S.; Valvano, M. A.; Foster, S. J.; Mak, T. W.; Nuñez, G.; Inohara, N. Nat. Immunol. 2003, 4, 702–707. doi:10.1038/ni945
    Return to citation in text: [1]
  24. Uehara, A.; Fujimoto, Y.; Kawasaki, A.; Kusumoto, S.; Fukase, K.; Takada, H. J. Immunol. 2006, 177, 1796–1804.
    Return to citation in text: [1]
  25. Girardin, S. E.; Travassos, L. H.; Hervé, M.; Blanot, D.; Boneca, I. G.; Philpott, D. J.; Sansonetti, P. J.; Mengin-Lecreulx, D. J. Biol. Chem. 2003, 278, 41702–41708. doi:10.1074/jbc.M307198200
    Return to citation in text: [1]
  26. Franchi, L.; Amer, A.; Body-Malapel, M.; Kanneganti, T. D.; Özören, N.; Jagirdar, R.; Inohara, N.; Vandenabeele, P.; Bertin, J.; Coyle, A.; Grant, E. P.; Nuñez, G. Nat. Immunol. 2006, 7, 576–582. doi:10.1038/ni1346
    Return to citation in text: [1]
  27. Miao, E. A.; Alpuche-Aranda, C. M.; Dors, M.; Clark, A. E.; Bader, M. W. Nat. Immunol. 2006, 7, 569–575. doi:10.1038/ni1344
    Return to citation in text: [1]
  28. Kanazawa, N.; Okafuji, I.; Kambe, N.; Nishikomori, R.; Nakata-Hizume, M.; Nagai, S.; Fuji, A.; Yuasa, T.; Manki, A.; Sakurai, Y.; Nakajima, M.; Kobayashi, H.; Fujiwara, I.; Tsutsumi, H.; Utani, A.; Nishigori, C.; Heike, T.; Nakahata, T.; Miyachi, Y. Blood 2005, 105, 1195–1197. doi:10.1182/blood-2004-07-2972
    Return to citation in text: [1]
  29. Carneiro, L. A.; Travassos, L. H.; Girardin, S. E. Ann. Med. 2007, 39, 581–593. doi:10.1080/07853890701576172
    Return to citation in text: [1]
  30. Inohara, N.; Ogura, Y.; Fontalba, A.; Gutierrez, O.; Pons, F.; Crespo, J.; Fukase, K.; Inamura, S.; Kusumoto, S.; Hashimoto, M.; Foster, S. J.; Moran, A. P.; Fernandez-Luna, J. L.; Nuñez, G. J. Biol. Chem. 2003, 278, 5509–5512. doi:10.1074/jbc.C200673200
    Return to citation in text: [1]
  31. Hugot, J. P.; Chamaillard, M.; Zouali, H.; Lesage, S.; Cézard, J. P.; Belaiche, J.; Almer, S.; Tysk, C.; O'Morain, C. A.; Gassull, M.; Binder, V.; Finkel, Y.; Cortot, A.; Modigliani, R.; Laurent-Puig, P.; Gower-Rousseau, C.; Macry, J.; Colombel, J. F.; Sahbatou, M.; Thomas, G. Nature 2001, 411, 599–603. doi:10.1038/35079107
    Return to citation in text: [1]
  32. Ogura, Y.; Bonen, D. K.; Inohara, N.; Nicolae, D. L.; Chen, F. F.; Ramos, R.; Britton, H.; Moran, T.; Karaliuskas, R.; Duerr, R. H.; Achkar, J.-P.; Brant, S. R.; Bayless, T. M.; Kirschner, B. S.; Hanauer, S. B.; Nuñez, G.; Cho, J. H. Nature 2001, 411, 603–606. doi:10.1038/35079114
    Return to citation in text: [1]
  33. Miceli-Richard, C.; Lesage, S.; Rybojad, M.; Prieur, A.-M.; Manouvrier-Hanu, S.; Hafner, R.; Chamaillard, M.; Zouali, H.; Thomas, G.; Hugot, J.-P. Nat. Genet. 2001, 29, 19–20. doi:10.1038/ng720
    Return to citation in text: [1]
  34. Maeda, S.; Hsu, L.-C.; Liu, H.; Bankston, L. A.; Iimura, M.; Kagnoff, M. F.; Eckmann, L.; Karin, M. Science 2005, 307, 734–738. doi:10.1126/science.1103685
    Return to citation in text: [1]
  35. Khan, P. M.; Correa, R. G.; Divlianska, D. B.; Peddibhotla, S.; Sessions, E. H.; Magnuson, G.; Brown, B.; Suyama, E.; Yuan, H.; Mangravita-Novo, A.; Vicchiarelli, M.; Su, Y.; Vasile, S.; Smith, L. H.; Diaz, P. W.; Reed, J. C.; Roth, G. P. ACS Med. Chem. Lett. 2011, 2, 780–785. doi:10.1021/ml200158b
    Return to citation in text: [1]
  36. NCI60 screening. http://dtp.nci.nih.gov/branches/btb/ivclsp.html.
    Return to citation in text: [1]

© 2013 Hershberger et al; licensee Beilstein-Institut.
This is an Open Access article under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The license is subject to the Beilstein Journal of Organic Chemistry terms and conditions: (http://www.beilstein-journals.org/bjoc)

 
Back to Article List